Moderna Reports Strong Q4 Results, Provides Investor Update
<p><a href='https://financialmodelingprep.com/financial-summary/MRNA'>Moderna (NASDAQ:MRNA) </a>reported its Q4 and full 2021-year earnings results and provided an investor update on Feb 24. </p>
<p>While reporting a strong quarter, the company also provided guidance for $19 billion in signed APAs for Spikevax (mRNA-1273), with $3 billion in additional signed options. However, the company noted that sales would be more weighted to the second half of the year. Management also gave bullish updates on the pipeline and on gaining COVID-19 vaccine market share back from lead companies Pfizer/BioNTech.</p>
<p>Analysts at Oppenheimer believe the company's stock is currently trading on potentially worst-case COVID-19 vaccine franchise dynamics and if the company can provide favorable pipeline updates in the next few quarters, the currently oversold stock could rebound.</p>

NASDAQ:MRNA